GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achilles Therapeutics PLC (STU:698) » Definitions » Net Margin %

Achilles Therapeutics (STU:698) Net Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Achilles Therapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Achilles Therapeutics's Net Income for the three months ended in Mar. 2024 was €-11.29 Mil. Achilles Therapeutics's Revenue for the three months ended in Mar. 2024 was €0.00 Mil. Therefore, Achilles Therapeutics's net margin for the quarter that ended in Mar. 2024 was 0.00%.

The historical rank and industry rank for Achilles Therapeutics's Net Margin % or its related term are showing as below:


STU:698's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -150.095
* Ranked among companies with meaningful Net Margin % only.

Achilles Therapeutics Net Margin % Historical Data

The historical data trend for Achilles Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achilles Therapeutics Net Margin % Chart

Achilles Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
- - - - -

Achilles Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Achilles Therapeutics's Net Margin %

For the Biotechnology subindustry, Achilles Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Achilles Therapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Achilles Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Achilles Therapeutics's Net Margin % falls into.



Achilles Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Achilles Therapeutics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-63.883/0
= %

Achilles Therapeutics's Net Margin for the quarter that ended in Mar. 2024 is calculated as

Net Margin=Net Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-11.292/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Achilles Therapeutics  (STU:698) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Achilles Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Achilles Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Achilles Therapeutics (STU:698) Business Description

Traded in Other Exchanges
Address
245 Hammersmith Road, London, GBR, W6 8PW
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing novel cancer immunotherapies targeting clonal neoantigens. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.

Achilles Therapeutics (STU:698) Headlines

No Headlines